NXTC today
$5.42-$0.56 (-9.36%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourExpanding
15 minDescending Triangle
5 minConsolidating
Daily trend turns up above $15.74
Key levels
Resistance$6.66
Resistance$5.60
Support$4.53
Support$1.60
Latest news & SEC filings
EarningsNextCure posts Q3 2026 results, issues business update
EarningsNextCure posts quarterly loss of $1.29 per share, topping $1.43 estimate
SEC FilingNextCure, Inc. filed a report on a major company event (Form 8-K)
All NXTC news →About NextCure
NextCure is a clinical-stage biopharmaceutical company developing targeted cancer therapies, mainly antibody-drug conjugates. Its lead candidates are SIM0505, aimed at CDH6, and LNCB74, aimed at B7-H4, both in Phase 1 testing for solid tumors such as ovarian, endometrial, breast, and lung cancers. The company also has earlier-stage oncology candidates, NC410 and NC525, plus two earlier-stage non-cancer antibody candidates. It operates in the United States and works with partners in China.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
NextCure, Inc. (NXTC)
What Is the Price Target for NXTC?
SEPT Low Target
$25.00
SEPT Mid Target
$25.00
SEPT High Target
$25.00
Analyst Consensus
$25.00
Is NXTC a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NXTC.
Start Free Trial →Is NXTC Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$20.23
10
Moat Score
NONE
1/9
Piotroski Score
-14.6
Altman Z-Score
What Is Smart Money Doing with NXTC?
Insider Signal
NEUTRAL
3 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% owner | Buy | 3,553 | $18K | Oct 27, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 1,672 | $8K | Oct 26, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | Buy | 5,626 | $27K | Oct 23, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NXTC Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
17.71%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for NXTC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NXTC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:02:03 | $5.44 | 1,000 | $$5K | SELL |
| 18:41:50 | $5.01 | 1,500 | $$8K | BUY |
| 18:04:51 | $5.55 | 1,048 | $$6K | SELL |
| 19:29:59 | $5.95 | 5,000 | $$30K | SELL |
| 17:59:51 | $5.99 | 7,100 | $$43K | BUY |
5 dark pool trades shown · $$91K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About NXTC
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for NXTC. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $BHRB — WILSON DAVID | Sale $2K $BHRB — WILSON DAVID | Sale $5K $NXTC — ADAR1 Capital Management, LLC | Sale $18K $AYI — GOLDMAN BARRY R | Sale $1.2M $FET — IVASCU JOHN C | Sale $36...
Join 3,500+ traders discussing NXTC in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for NextCure, Inc. (NXTC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NXTC — frequently asked questions
What is NXTC stock price today?
NextCure, Inc. (NXTC) is at $5.42, down 9.36% (-$0.56) at the Nov 12, 2026 close.
Why is NXTC stock moving today?
Latest NXTC news — Nov 11, 2026: NextCure posts Q3 2026 results, issues business update · Nov 10, 2026: NextCure posts quarterly loss of $1.29 per share, topping $1.43 estimate
What is the NXTC price target?
The average analyst price target for NXTC is $25.00, ranging from $25 to $25, based on 1 analysts. Latest: LUCID CAPITAL MARKETS initiates on May 11, 2026.
What do analysts rate NXTC?
Analyst ratings for NXTC: 1 Buy, 0 Hold, 0 Sell — consensus Buy.
Did NXTC beat earnings?
NXTC last reported on Aug 6, 2026: EPS -$2.80 vs -$1.95 expected — a miss of 43.6%.
Does NXTC pay a dividend?
NXTC does not currently pay a dividend.
What are NXTC support and resistance levels?
Support: $4.53, $1.60. Resistance: $5.60, $6.66, $7.52.
What are insiders doing with NXTC?
Insider activity: NEUTRAL, 3 buys and 0 sells in the last 90 days.
What is the latest news on NXTC?
Nov 11, 2026: NextCure posts Q3 2026 results, issues business update · Nov 10, 2026: NextCure posts quarterly loss of $1.29 per share, topping $1.43 estimate · Nov 10, 2026: NextCure, Inc. filed a report on a major company event (Form 8-K)